

- **Name:** Jaemoon Koh
  - **Current Position & Affiliation:** Clinical associate professor  
Department of Pathology  
Seoul National University Hospital
  - **Country:** Korea
- 

- **Educational Background:**

- 2012.9-2019.8 PhD, Pathology, Graduate School, Seoul National University College of Medicine, Seoul, Republic of Korea
- 2006.3-2010.2 M.D. Seoul National University College of Medicine
- 2004.3-2006.2 Premedical Course, Seoul National University College of Natural Science, Seoul, Republic of Korea

- **Professional Experience:**

- 2024.3-present Clinical associate professor, Department of Pathology, Seoul National University Hospital
- 2020.3-2024.2 Clinical assistant professor, Department of Pathology, Seoul National University Hospital
- 2019.3-2020.2 Clinical fellow in Pathology, Seoul National University Hospital
- 2015.9-2018.9 Technical research personnel, laboratory of Immune Regulation in Department of Biomedical Sciences, Seoul National University College of Medicine
- 2011.3-2015.2 Resident in Pathology, Seoul National University Hospital
- 2010.3-2011.2 Intern, Seoul National University Hospital

- **Professional Organizations:**

Korean Society of Pathologists  
Korean Association of Immunologists  
Korean Association for Lung Cancer  
American Association for Cancer Research

- **Main Scientific Publications:**

1. Jeon YK, **Koh J**, Lee D, Kim S, Song SG, Han B, Jeong H, Kim YA, Keam B, Lee SH, Kim K, Chung DH. Spatially resolved whole-transcriptomic and proteomic profiling of lung cancer and

- its immune-microenvironment according to PD-L1 expression. *Cancer Immunol Res.* 2024 Dec 3;12(12):1753-1764.
2. Oh S, **Koh J**, Kim TM, Kim S, Youk J, Kim M, Keam B, Jeon YK, Ku JL, Kim DW, Chung DH, Heo DS. Transcriptomic Heterogeneity of EGFR-Mutant Non-Small Cell Lung Cancer Evolution Toward Small-Cell Lung Cancer. *Clin Cancer Res.* 2024 Oct 15;30(20):4729-4742.
  3. **Koh J**, Kim S, Kim JY, Yim JJ, Kwak N. Immunologic features of nontuberculous mycobacterial pulmonary disease based on spatially resolved whole transcriptomics. *BMC Pulm Med.* 2024 Aug 13;24(1):392.
  4. **Koh J**, Woo YD, Yoo HJ, Choi JP, Kim SH, Chang YS, Jung KC, Kim JH, Jeon YK, Kim HY, Chung DH. De novo fatty-acid synthesis protects invariant NKT cells from cell death, thereby promoting their homeostasis and pathogenic roles in airway hyperresponsiveness. *Elife.* 2023 Nov 2;12:RP87536.
  5. Yeon M, Lee H, Yeo J, Jeong MS, Jung HS, Lee H, Shim K, Jo H, Jeon D, **Koh J**, Jeoung D. Cancer/testis antigen CAGE mediates osimertinib resistance in non-small cell lung cancer cells and predicts poor prognosis in patients with pulmonary adenocarcinoma. *Sci Rep.* 2023 Sep 21;13(1):15748.
  6. **Koh J**, Kim S, Woo YD, Song SG, Yim J, Han B, Lim S, Ahn HK, Mun S, Kim JS, Keam B, Kim YA, Lee SH, Jeon YK, Chung DH. TCF1+PD-1+ tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer. *Eur J Cancer.* 2022 Oct;174:10-20.